Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Trius Therapeutics Initial Offer Raises $50 Million

Trius Therapeutics Inc. raised $50 million in an initial public offering after the developer of antibiotics delayed the IPO last week and cut the size of the sale by more than 40 percent.

The drugmaker priced 10 million shares at $5 each yesterday after originally offering 6 million for $12 to $14, according to a statement and Securities and Exchange Commission filings. The San Diego-based company will use proceeds to fund clinical drug trials and research and development, the filings showed.

Trius Therapeutics was the first of seven U.S. IPOs scheduled for this week, according to data compiled by Bloomberg. Filings for initial sales climbed to the highest since 2007 last quarter even as deals were shelved at the fastest rate worldwide since the collapse of New York-based Lehman Brothers Holdings Inc.

Citigroup Inc. of New York led the offering from Trius Therapeutics, which closed unchanged at $5 in Nasdaq Stock Market trading today.

NXP Semiconductors NV, the Eindhoven, Netherlands-based chipmaker owned by KKR & Co. and Bain Capital LLC, is seeking to raise $714 million on Aug. 5 in the biggest U.S. offering of 2010. IntraLinks Holdings Inc., a New York-based provider of document exchange services for the loan market, may sell as much as $202.4 million including an overallotment option, according to SEC filings and data compiled by Bloomberg.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.